Introduction
Dementia encompasses a group of chronic neurodegenerative diseases that affected an estimated 44.4 million people worldwide in 2013. Because of an increasingly aging population, it is predicted that this figure will rise to an estimated 75.6 million by 2030 and 135.5 million by 2050 (Prince et al., 2013) . The worldwide cost of dementia was estimated to be $604 billion in 2010 (Wimo & A.s.D. International, 2010 ). Alzheimer's disease (AD) is the most common form of dementia, accounting for~60%-80% of cases worldwide (Lobo et al., 2000) . AD is characterized by the accumulation of extracellular amyloid-β (Aβ) plaques, intracellular neurofibrillary tangles of hyperphosporylated tau, and widespread gliosis in the brain (Serrano-Pozo et al., 2011) . Despite the progress that has been made in understanding the cellular pathology of AD, available treatments only temporarily alleviate some symptoms and do not modify the underlying disease process. By the time an individual becomes symptomatic, there are already considerable neuronal cell loss, plaque deposition, and tangle burden within the brain, which can appear up to 10 years before a clinical diagnosis is made (Jack et al., 2010) . Reflecting the growing public health and socioeconomic burden of AD, there has been a year-on-year increase in the number of publications investigating the etiology of the disease (Fig. 1) as researchers seek novel disease-modifying treatments.
Although the neuropathology associated with AD has been well described, little is known about the mechanisms underlying disease onset and progression. Quantitative genetic analyses demonstrated high heritability estimates (58%-79%) for AD (Gatz et al., 2006) , and thus, initial approaches to understanding etiology focused on uncovering a genetic contribution to disease susceptibility. In recent years, the recruitment of large cohorts and the relatively inexpensive cost of assessing genetic variation through genome-wide association studies (GWAS) have allowed the identification of multiple variants associated with an elevated risk of developing AD. Many of these genes have also been robustly associated with AD via subsequent meta-analyses (Harold et al., 2009; Hollingworth et al., 2011; Lambert et al., 2013a; Naj et al., 2011) , and most recently, polygenic risk scores for AD have been developed (Escott-Price et al., 2015) . Collectively, common single nucleotide polymorphisms (SNPs) are believed to only account for 33% of attributable risk (Ridge et al., 2013) , and the mechanism behind their action remains largely unknown. Exome-sequencing projects have also identified other variants, for example, TREM2 (Guerreiro et al., 2013) , which have a larger effect size, yet these are relatively rare. In recent years, researchers have used epigenome-wide association studies (EWAS) to identify epigenetic changes in disease with the aim to elucidate additional mechanisms of pathology, which may provide a link to environmental factors.
Epigenetic processes mediate the reversible regulation of gene expression, occurring independently of DNA sequence variation and acting principally through chemical modifications to DNA and nucleosomal histone proteins. Dynamic changes to the epigenome orchestrate a diverse range of important neurobiological and cognitive processes in the brain (Lunnon & Mill, 2013) . DNA methylation is the best characterized and most stable epigenetic modification which modulates the transcription of mammalian genomes. This is due to its ability to be interrogated using archived genomic DNA resources, which are the focus of most human epidemiological epigenetic research to date (Lunnon & Mill, 2013) . The methylation of a cytosine in a CpG dinucleotide by DNA methyltransferase enzymes forms 5-methylcytosine, which can disrupt the cell's transcriptional machinery by blocking the binding of transcription factors and attracting methyl-binding proteins that initiate chromatin compaction and bring about gene silencing (Klose & Bird, 2006) . The predominant focus to date is methylation within CpG islands located within the 5′ promoters of many constitutively expressed housekeeping control genes. However, recent data suggest that the relationship between DNA methylation and transcription may be more complex, with gene body methylation and non-CpG methylation often being associated with active gene expression (Aran et al., 2011; Ball et al., 2009; Hellman & Chess, 2007; Lister et al., 2009) and alternative splicing (Flores et al., 2012; Lyko et al., 2010) . The mechanisms involved in cytosine demethylation have also been studied; its demethylation by ten-eleven translocation (TET) enzymes leads to a stepwise change in the cytosine side chain state from methylated cytosine to hydroxymethylated cytosine (5-hmC), to formyl cytosine, to carboxyl cytosine, and finally back to unmodified cytosine by a yet unclassified enzyme/mechanism (Hill et al., 2014) . Each of these intermediates may have their own effect on gene transcription, splicing, and subsequent protein function, and recent studies have shown 5-hmC to be at high levels in the brain (Nestor et al., 2012; Song et al., 2011) , with variation across different anatomical regions (Lunnon et al., 2016) . Recent advances in genomic technology have allowed the first genome-scale studies assessing methylomic variation (EWAS) in AD. These studies have identified AD-associated DNA methylomic variation at numerous loci in the cortex, with consistent findings across multiple independent study cohorts, in addition to brain-region-specific changes and blood DNA methylation signatures De Jager et al., 2014) . In addition, a recent paper by Yu et al. combined genetic and epigenetic findings by examining DNA methylation patterns across genes that have previously been nominated by GWAS, identifying several overlapping loci (Yu et al., 2014) .
Although GWAS and EWAS analyses have identified multiple genes associated with AD, the extent to which common pathways are shared in the findings across studies has not yet been explored. This review aims to integrate the most robust findings from GWAS, exome sequencing studies, and EWAS performed to date in AD to highlight common molecular pathways, which could ultimately aid in the identification of novel pharmacological targets for the disease.
Methods
Using the publically available online search GWAS catalogue (https://www.ebi.ac.uk/gwas/search?query=Alzheimer%27s% 20disease#association) and a P value cutoff of P b 5 × 10 −8
, we identified 45 unique GWAS in AD totaling 144 SNPs. We then removed studies based on poor sample size (b 1000 total samples) as well as those studies that included samples that were non-European in origin. Following the study selection, SNPs in intronic regions were removed from the analysis. After filtering for associated disease outcome measures, including the terms Dementia and core Alzheimer's disease neuropathological changes, Alzheimer's disease late onset, Alzheimer's disease, Psychosis and Alzheimer's disease, Alzheimer's disease age of onset, Alzheimer's disease biomarkers, and Neurofibrillary tangles, we were left with 22 studies with 49 SNPs in 32 unique genes (Table 1A ) (Harold et al., 2009; Hollingworth et al., 2011; Lambert et al., 2013a; Naj et al., 2011; Coon et al., 2007; Webster et al., 2008; Li et al., 2008; Kamboh et al., 2012a; Kamboh et al., 2012b; Lambert et al., 2009; Seshadri et al., 2010; Naj et al., 2010; Perez-Palma et al., 2014; Nelson et al., 2014; Abraham et al., 2008; Antunez et al., 2011; Hollingworth et al., 2012; Cruchaga et al., 2013; Hu et al., 2011; Lambert et al., 2013b; Beecham et al., 2014; Jonsson et al., 2013) . Four genes were identified from exome sequencing studies (Guerreiro et al., 2013; Guerreiro et al., 2012; Cruchaga et al., 2014; Pottier et al., 2012) by performing a literature search in PubMed using the phrases Alzheimer's disease and Exome sequencing alone and in combination (Table 1B) . Genes from EWAS were compiled from the 2014 publications by Lunnon et al. and De Jager et al. including (Lambert et al., 2013a) (continued on next page) (Lambert et al., 2013a) (continued on next page) (Lambert et al., 2013a) 2012 publication by Bakulsk et al. was excluded from the analysis based on sample size (Bakulski et al., 2012) . Gene names were checked against quoted genomic location using the UCSC Genome Browser; only genes containing a probe of interest were included. The resulting gene list contained 48 unique genes that met the criteria for inclusion for our study (Table 2) . Gene annotation for all genes of interest were taken from the Gene Ontology (GO) Consortium database, where available, and supplemented with information from the Entrez gene database. Two genes overlapped between GWAS and exome sequencing studies (TREM2, SORL1), and 1 gene overlapped between GWAS and EWAS (BIN1), bringing the total number of genes across all analyses to 81.
Pathways
The 81 genes identified were compared in terms of their molecular/cellular function and grouped by pathways in which the identified genes operate. By taking significant loci across multiple (Lambert et al., 2013a) Shown are the genes identified from GWAS and their respective SNPs, associated P value, GO annotation, chromosome and genomic position, and the relevant study. Only SNPs with Pb 5 × 10 −8 were included. (Cruchaga et al., 2014) Shown are the genes identified from exome sequencing studies and their respective SNPs, GO annotation, chromosome and genomic position, and the relevant study. Jager et al., 2014) study designs, we identified 5 common pathways altered at the genetic and/or epigenetic level in AD: plasma membrane and cytoskeletal processes, lipid homeostasis, synaptic signaling, immune cell processes, and mitochondrial processes (Fig. 2) . The largest number of genes fell into the functional group plasma membrane and cytoskeletal processes (n = 14); however, this could be due to the fact that this is a proportionally larger pathway and is therefore more likely to contain an associated gene by chance. Of the pathways we have identified, many of them have considerable overlap; for example, lipid processes are intrinsically linked to the plasma membrane which is composed of phospholipids and a large percentage of cholesterol. To better understand the overlap between GWAS and EWAS nominated genes, we looked at the cellular localization of genes from each type of study (Fig. 3) . The 2 largest localization groups (cellular membrane and nucleus) were consistent between methodologies. This would, to some degree, be expected (Table 1A) are shown in black. The 48 most significant EWAS loci (red) were identified from De Jager et al. (2014) and Lunnon et al. (2014) (Table 2 ). The 4 green loci were identified via exome sequencing from Cruchaga et al. (2014) , Guerreiro et al. (2012) , (2013), and Pottier et al. (2012) (Table 1B) . We next compared the molecular and cellular pathways of the proteins encoded by these genes to look for functional overlap between studies. Jager et al., 2014) Shown are the genes identified from EWAS and their respective probes, associated P value, GO annotation, chromosome and genomic position, and the relevant study. Only probes with P b 1 × 10 −7 were included.
because the majority of total proteins are involved in these locations and, in addition, current protein research has focused on these areas of the cell.
To provide a more structured approach to pathway analysis, all 81 genes were entered into the PANTHER pathway analysis using the enrichment analysis from gene ontology consortium (Mi et al., 2013) . Fourteen biological process and 4 cellular component pathways were identified after passing Bonferroni correction. Most pathways reflected an interaction with Aβ or other AD pathology (Fig. 4) . As the data for these genes were most likely collected from AD publications, the resulting pathways are not unexpected but are most likely to be limited.
Plasma membrane/cytoskeleton
This is the pathway which contained the largest number of associated genes from our analysis (n = 14). The plasma membrane insulates the intracellular components from the extracellular environment, as well as catalyzing the transport of specific compounds, including nutrients and ions. Phospholipids that make up the membrane provide suitable fluidity and permeability. Alterations in the receptor function, membrane integrity, and membranedependent processes seen in AD have been reviewed by A. Farooqui et al. (Farooqui et al., 1995) . The cytoskeleton provides contractility and couples biochemical responses with mechanical stresses in cells. It is vital in the movement of cellular machinery around the cell and to the membrane, as well as orchestrating the procedures needed for cellular movement and reshaping, a function specifically important to the microglial cells of the brain in the response to inflammation (Sheng et al., 1997) . For an overview of cell mechanics and the cytoskeleton, see the review by Fletcher and Mullins 2010 (Fletcher & Mullins, 2010) . The inability of neurons to regulate calcium homeostasis through cell surface ion channels is an aspect of AD pathogenesis that appears to be intimately involved in the dysfunction and death of neurons (Mattson, 2004) . Familial AD mutations in APP and PSEN1 support a role for perturbed calcium regulation in AD (Mattson, 2004) . In addition, all of the enzymatic machinery responsible for the generation of the pathogenic Aβ plaque formation are plasma membrane based (Lukiw, 2013) , suggesting that damage to the plasma membrane may be a key factor in the Aβ pathology typical of AD.
BIN1 has been nominated by both GWAS and EWAS, and in addition to its role in synaptic signaling, it also has a role in plasma membrane/cytoskeletal processes because it acts as an amphiphysin, which is known to promote caspase-independent apoptosis as well as play an important role in neuronal membrane organization (Wigge et al., 1997) . Major learning defects and seizures have been linked to decreased expression of amphiphysins in murine brain (Di Paolo et al., 2002) . In addition, altered expression of BIN1 has been shown in aging mouse models of AD (Yang et al., 2008) , providing further evidence for its role in AD pathology. Despite having no previous link to AD, ANK1 is now the one of the strongest reported candidate genes in AD EWAS, with strong links to cell structure. ANK1 was found to be hypermethylated in AD brain in 2 separate studies, including 1 with 2 independent validation cohorts De Jager et al., 2014) . The differentially methylated region in this gene spans at least 6 CpG sites and was significantly associated with neuropathology in cortical regions but not cerebellum or premortem blood , indicating tissue specificity of the differentially methylated region to regions of neuropathology. ANK1 is found in multiple different isoforms, with some transcript variants specific to the brain (Gallagher et al., 1997) and some evidence for differential splicing in AD . As with BIN1, one of the main functions of ANK1 is compartmentalization and maintenance of the plasma membrane, and it is possible that the altered expression of this gene could lead to neuronal membrane dysfunction in AD .
The PVRL2 gene identified by GWAS encodes a single-pass type I membrane glycoprotein, which is one of the plasma membrane components of adherens junctions. Cell to cell connections brought about by adherens junctions are vital for effective neuronal signaling (Marambaud et al., 2002) . Interestingly, Marambaud et al. used various immunological-based methods to investigate the PSEN1/ γ-secretase system, where mutations are associated with familial AD, and showed that it disrupted adherens junctions in AD (Marambaud et al., 2002) . Expression of PVRL2 has been detected in many organs including the brain, and it was later suggested that it was associated with human longevity along with the AD GWAS nominated loci TOMM40 and APOE (Lu et al., 2014) . In addition, Elias-Sonnenschein et al. showed a significant correlation between the GWAS nominated locus MS4A4A and Aβ but not tau pathology in AD (Elias-Sonnenschein et al., 2013) . Despite this, there is little to no research on the specific function of MS4A4A, although the gene product is associated with GO pathways that indicate that it is an integral component of the plasma membrane. Two other genes within the MS4A gene cluster have also been nominated via GWAS: MS4A4E and MS4A6A (Hollingworth et al., 2011; Lambert et al., 2013a) . One recent study demonstrated that MS4A6A genotype and AD are associated with differential expression of isoform variants in blood and some brain regions (Proitsi et al., 2014) .
Lipid homeostasis
Recent epidemiological, molecular, and biochemical evidence has strengthened the hypothesis that cholesterol is a risk factor for AD, and although cholesterol homeostasis in the brain is largely unexplored, new findings strongly support the involvement of cholesterol in both the generation and deposition of Aβ (Puglielli et al., 2003) . Specifically, the quantity of cholesterol in the neuronal plasma membrane has been shown to make neurons more susceptible to the damage caused by Aβ in AD (Arispe & Doh, 2002) . Other studies suggest that cholesterol acts directly on the amyloid cascade by promoting amyloidogenic processing of APP (Mattson, 2004) . Interestingly, statins, which are a class of cholesterol-lowering drugs, decrease Aβ levels as well as plaque deposition in APP transgenic mouse models (Fassbender et al., 2001 ). In addition, high cholesterol levels and changes to cholesterol metabolism can increase the production of Aβ in cell culture and murine models (Puglielli et al., 2003) . Three of the most significant genes from AD GWAS are associated with lipid metabolism (APOE, APOC1, CLU). APOE was first identified as a risk factor for AD in 1993 (Strittmatter et al., 1993) using immunostaining and genotyping analysis of 30 AD cases and 91 controls. Since 2006 and the wide application of GWAS to AD research (Grupe et al., 2007) , the APOE polymorphism has been successfully replicated in several other studies (Coon et al., 2007; Abraham et al., 2008; Kramer et al., 2011; Logue et al., 2011; Meda et al., 2012; Ramanan et al., 2014) , making APOE the most robust gene linked to late-onset AD (LOAD) risk to date. The proportion of genetic variance for LOAD risk attributed to APOE genotype is estimated to be 10%-20% (Slooter et al., 1998) . APOE is a 299-amino acid glycoprotein and the major protein component of very low density lipoproteins, the major apolipoprotein in the brain (Puglielli et al., 2003) , as well as having a functional role in cholesterol and triglyceride metabolism (Breslow et al., 1982) . There are 3 APOE alleles that affect one's risk of AD (ε2, ε3, and ε4), in addition to age of onset (Roses & Allen, 1996) . Of the 3 alleles, APOE ε2 demonstrates a protective effect, with an odds ratio of 0.3 for possessing one ε2 allele, whereas APOE ε4 is associated with a higher LOAD risk, with an odds ratio of 4.4 and 19.3, respectively for having 1 or 2 alleles (Corder et al., 1994) , as well as a younger median age of dementia onset (Corder et al., 1994; Reiman et al., 2007) . It has been suggested that the mutated APOE hinders clearance of soluble Aβ protein from the brain, leading to Aβ aggregation into fibrils. Furthermore, APOE has been shown to promote neurodegeneration by directing the toxic Aβ oligomers to synapses (Ramanan et al., 2014) . However, a recent positron emission tomographic study to measure Aβ in 602 individuals found that the ε4 allele is neither necessary nor sufficient for the development of AD pathology (Ramanan et al., 2014) .
SORL1 has been identified in several studies of AD using GWAS and exome sequencing methods; in addition, Yu et al. found epigenetic changes in this gene (Yu et al., 2014) . It has many functional domains with different functions, including cargo transport, chaperone-like activity, signaling, and intracellular sorting (Jacobsen et al., 2001) . When acting as a sorting receptor, the SORL1 gene product protects APP from being directed to the endosome where it would be cleaved by β-secretase, producing Aβ (Louwersheimer et al., 2015) . Furthermore, SORL1 can bind APOE, making SORL1 an important component in the pathophysiology of AD (Elias-Sonnenschein et al., 2013) .
Synaptic signaling
Synaptic dysfunction is possibly the best established of all the proposed pathological mechanisms for AD to date, as it shows clear progression throughout the entire disease, including presymptomatic changes (Masliah et al., 2001) . Early stages of AD are characterized by a 25%-35% decrease in numerical density of synapse per cortical region (Davies et al., 1987) . There has also been evidence that the loss of synapses correlates with the soluble pool of cortical Aβ (Lue et al., 1999) . Stereological and biochemical analyses have shown that the reduction in synaptic density within AD brain correlates with cognitive defects better than the traditional hallmarks of Aβ plaques and neurofibrillary tangles (Masliah et al., 2001) .
We have identified 4 genes from GWAS and EWAS analyses of AD that have been linked to synaptic function. Two of these, BIN1 and PICALM, have functions in vesicular trafficking. Specifically, studies have shown that the BIN1 gene has roles in a number of specific pathways, including clathrin-mediated endocytosis which is an essential step in the intracellular trafficking of proteins and lipids such as nutrients, growth factors, and neurotransmitters in synapses (Cousin & Robinson, 2001; Dreyling et al., 1996; Wigge & McMahon, 1998) . Originally identified as a tumor suppressor (Sakamuro et al., 1996) , the BIN1 gene product is expressed most abundantly in brain and muscle (Wechsler-Reya et al., 1997) , with several alternatively spliced brain-specific isoforms. BIN1 is one of the few genes reproducibly identified by GWAS that does not fall near or within the APOE locus; in addition, it is the only gene in our analysis to be significantly associated with AD in both GWAS and EWAS.
Like BIN1, PICALM is also involved in clathrin-mediated endocytosis (Dreyling et al., 1996) . PICALM directs the trafficking of the VAMP2 protein. VAMP2 is a SNARE protein that plays a key role in the fusion of vesicles to the presynaptic membrane, allowing neurotransmitter release into the synapse, a process essential to neuronal function (Harel et al., 2008) . PICALM has been robustly identified as a risk factor for AD via GWAS (Harold et al., 2009; Seshadri et al., 2010) ; however, AD-linked SNPs identified in PICALM may still be affected by APOE genotype because of the large amount of attenuation seen when adjusted for APOE status (Hu et al., 2011) . Jun et al. have also reported this interaction observing that genotypes of PICALM conferred risk predominantly in APOE ε4-positive participants, providing strong evidence for a synergistic effect (Jun et al., 2010) . PICALM is also thought to affect amyloid precursor protein processing via endocytic pathways (Harold et al., 2009) .
As a previously known risk factor gene for AD (Lambert et al., 2013a) , PTK2B was shown via network analyses to be linked to RHBDF2, ANK1, and RPL13, which were recently nominated from EWAS, providing further evidence for a role in AD pathology (De Jager et al., 2014) . PTK2B has a number of roles including the induction of long-term potentiation of nerve cells, a central process of memory formation; cell migration; and synaptic function (Lambert et al., 2013a) .
Immune cell dysfunction (astrocytes, oligodendrocytes, and microglia)
There is a widely accepted link between inflammation, the immune system, and AD pathology (Adriana Martorana et al., 2012; Akiyama et al., 2000; Monson et al., 2014; Salminen et al., 2009; Tuppo & Arias, 2005) ; more specifically, the inflammation seen in AD has been proposed to exacerbate symptoms (Akiyama et al., 2000) . Microglia, which are the brain's resident macrophages, have been shown to increase their viability by 22.0%-29.4% in response to fibrillar Aβ deposits of 0.2 to 5.0 μmol/L, which are commonly seen in AD. Oligomeric Aβ at a dose of 5.0 μmol/L results in cytotoxic microglia (Pan et al., 2011) and ultimately leads to synaptic degeneration and neuronal death (Barger & Basile, 2001 ). However, relatively few genes that have shown robust associations with AD have been directly linked with inflammation or immune functions. Most noteworthy, a rare variant in TREM2 was recently recognized by a number of AD exome sequencing studies and GWAS (Guerreiro et al., 2013; Jonsson et al., 2013; Forabosco et al., 2013; Neumann & Daly, 2012) . TREM2 encodes an innate immune system receptor on the surface of microglial cells within the brain. With the signaling counterpart DAP12 (also called TYROBP), TREM2 forms a molecular complex that promotes phagocytosis of bacteria (N'Diaye et al., 2009) . Work by Takahashi et al. has shown that TREM2 also has a role in the clearance of apoptotic neurones due to its ability to increase migration and phagocytosis of microglia (Takahashi et al., 2005) . Recently, 1 study demonstrated correlation in TREM2 and CD33 gene expression in AD (Chan et al., 2015) . As CD33 has also been nominated in various AD GWAS (Hollingworth et al., 2011; Naj et al., 2011; Kamboh et al., 2012b) , this provides further evidence for an overlap of AD gene pathways in disease. As described above, recent protein-protein interaction data also demonstrated that several EWAS nominated loci (ANK1, RHBDF2, PICLAM) have a functional link to PTK2B (De Jager et al., 2014) . PTK2B is an AD risk factor gene that plays a key role in the signaling cascade involved in the modulation of microglial and infiltrating macrophage cell activation (De Jager et al., 2014) .
A further gene related to immune function is RHBDF2, identified by EWAS. Differentially methylated CpG sites close to the RHBDF2 gene were identified in 2 independent EWAS De Jager et al., 2014) , with recent studies showing that this increases RHBDF2 expression in AD brain (De Jager et al., 2014) . RHBDF2 transports TNFα converting enzyme (TACE, also called ADAM17), which is necessary for the release of TNFα from the cell surface (Adrain et al., 2012) . RHBDF2 absence in mice affects the release of TNFα from the cell surface (Siggs et al., 2012) and therefore impairs systemic immune responses to pathogens (McIlwain et al., 2012) , although the brain phenotype has yet to be researched.
Mitochondrial processes
Mitochondrial dysfunction is one of the most prominent characteristics of AD in both the brain and the periphery (Devall et al., 2016; Devall et al., 2014; Lunnon et al., 2012) , with TOMM40, one of the most robust genes identified from GWAS, associated with mitochondrial function. This gene is located approximately 2 kilobases downstream from APOE, and because of the locality of these 2 genes, there is strong linkage disequilibrium (LD) for TOMM40 with the APOE locus (Feulner et al., 2010) ; hence, many studies have failed to find an association of TOMM40 in AD after adjusting for APOE genotype (Ramanan et al., 2014; Wijsman et al., 2011; Yu et al., 2007) . However, 1 study reports TOMM40 as a possible risk factor of AD independent of APOE (Lutz et al., 2010) . Specifically, this study found a poly-T track mutation in TOMM40 that acts independently of APOE genotype, which has also seen been reported in another independent study (Cruchaga et al., 2011) . In addition to increasing risk of developing AD, TOMM40 has also been linked to an earlier age of onset for the disease (Roses et al., 2009) . Other studies also suggest that TOMM40 provides an additional risk for AD, in addition to APOE (Potkin et al., 2009; Takei et al., 2009 ). However, until the extent of the LD between TOMM40 and APOE is fully characterized, it will be difficult to pinpoint the exact effect the TOMM40 mutation has on LOAD pathogenesis.
CLU has various nuclear and mitochondrial isoforms and is thought to regulate the rate of cell proliferation. CLU has been consistently replicated across many GWAS and holds a strong association with AD (Harold et al., 2009; Lambert et al., 2009; Jun et al., 2010; Wijsman et al., 2011) . The nuclear isoforms result in the promotion of apoptosis, whereas mitochondrial isoforms of CLU suppress BAX-dependent release of cytochrome c into the cytoplasm and inhibit apoptosis (Zhang et al., 2005) . As an increased level of apoptosis in the brain is seen in AD, it could suggest a role of CLU mutations in pathogenesis (Behl, 2000) . SPG7 was identified by EWAS and encodes a mitochondrial metalloprotease protein. Mitochondrial proteases degrade misfolded and nonassembled polypeptides. They also regulate the activity of specific substrates by mediating essential processing steps. These proteases have been hypothesized to play a role in neurodegenerative diseases by affecting neuronal maintenance and axonal function (Martinelli & Rugarli, 2010) .
Discussion
The use of GWAS to identify common disease variants in AD has been at the forefront of research to understanding disease etiology for 10 years. More recently, the falling cost of exome and whole genome sequencing has identified rarer variants with a larger effect size. However, only 3 EWAS have been reported in AD to date (Lunnon et al., 2014; De Jager et al., 2014; Bakulski et al., 2012) , which have solely focused on DNA methylation, although further studies are highly anticipated. Of all the genes identified from GWAS and EWAS in AD, only 1 locus was found to be overlapping between these 2 methodologies (BIN1).
As with any pathway identification analysis, there are caveats to our method. Some pathways are significantly larger than others containing more genes; therefore, using this method, we are more likely to find associated genes in these pathways over others. Secondly, cellular pathways that contain a gene which is either genetically or epigenetically altered may still be able to function normally, as similar proteins could "step-in" to fulfill the lost functionality. Thirdly, in our analysis, we did not filter our results based on loss of function SNPs or reduced expression; therefore, despite the alterations in AD, the genes we have identified may well have no change in their functionality. Fourthly, AD is characterized by neuronal cell loss and gliosis, and thus, the findings from EWAS may simply represent an alteration in cellular abundance, and although EWAS can apply cell-specific corrections to methylation data (Guintivano et al., 2013) , this was not included in our analysis. The ability to look at single-cell epigenetic profiles in disease would allow researchers to conclusively quantify changes that occur at both cellular and disease-state levels; however, single-cell isolation in postmortem tissue, via laser capture microdissection or florescent-assisted cell sorting, currently represents a considerable challenge to the field. Finally, epigenetic research in AD is still in its early stages with only 2 EWAS included in our analysis; this coupled with the fact that current methylation data are the sum of 2 different cytosine modifications (5-methylcytosine and 5-hmC) means that we may have an underrepresentation of significant EWAS genes in AD. A further caveat of epigenetic studies compared with genetic studies is that causality is more difficult to establish, and thus, further studies examining the functional role of nominated EWAS loci are warranted.
Conclusion
Looking at the most significant genetic and epigenetic findings in AD to date, we have identified several pathways that require further exploration and could ultimately aid in our understanding of AD etiology. Well-characterized clinical cohorts will also allow the identification of further rare variants of AD, whereas advances in methodologies are also allowing the identification of other epigenetic marks, such as histone modifications and other DNA modifications at single-nucleotide resolution (Lunnon & Mill, 2013) . A number of recent studies have demonstrated altered global levels of 5-hmC in AD brain (Condliffe et al., 2014; Chouliaras et al., 2013) ; however, studies to investigate loci-specific 5-hmC changes in AD are yet to be published. There is also the potential for further disease mechanisms to be identified from current studies as research moves to integrate GWAS and EWAS data in the same data sets to identify cis methylation quantitative trait loci. Ultimately, integrating genomic and epigenomic data with other "omic" modalities will allow the identification of novel dysfunctional pathways in disease (Lunnon & Mill, 2013) .
